BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CSL Biotherapies Initiates Shipments of Its Seasonal Influenza Vaccine to U.S. Customers


8/7/2013 8:32:22 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KING OF PRUSSIA, Pa., Aug. 6, 2013 /PRNewswire/ -- CSL Biotherapies, Inc. announced today that shipment of its seasonal influenza vaccine for the 2013-2014 season has started.

"Given the magnitude of influenza burden in the U.S. and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before," said Dr. Marie Mazur, Head of Worldwide Commercial Operations, Influenza. "CSL Biotherapies is committed to addressing this public health need by consistently delivering its influenza vaccine early to the healthcare providers in the United States."

CSL Biotherapies will ship approximately 11 million doses of the seasonal flu vaccine to the United States for the upcoming season. Shipment will comprise multi-dose and pre-filled syringe presentations.

About CSL Biotherapies, Inc.
CSL Biotherapies, Inc., located in King of Prussia, PA, is the U.S. headquarters of bioCSL. Parent company CSL Limited has manufactured influenza vaccine in its Melbourne, Australia facility since 1968. CSL Limited has made a $60 million (U.S.D.) investment in plant and equipment to double capacity at its Melbourne facility, making it one of the largest vaccine manufacturing facilities in the world. CSL-branded influenza vaccines are approved in 28 countries.

At bioCSL, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which also includes CSL Research & Development, CSL Plasma, and CSL Behring, has more than 11,000 employees globally and operates in 26 countries around the world.

Media Contact:
Sheila Burke
610-878-4209

SOURCE CSL Biotherapies, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES